P21 (P-21 / P021)

Published · Researched 2026-09-21

Deep-research package — Cognitive & Nootropic category. Extraction date: 2026-09-20.

1. Overview

P21 (synonym P021) is a synthetic research peptide derived from a small biologically active fragment of ciliary neurotrophic factor (CNTF). Vendor literature describes it as engineered for stability and blood–brain-barrier penetration, unlike the full CNTF protein. Per Liberty Peptides' published specs: sequence DGGL, molecular formula C27H42N6O8, molecular weight 578.7 g/mol (note: Peptide Works lists a conflicting formula C30H54N605 — discrepancy UNVERIFIED). It is sold only as a gray-market research chemical in lyophilized vials (2 mg, 5 mg, 10 mg). There are no published human trials; the evidence base is preclinical (mouse models of Alzheimer's/cognitive aging, 2014–2022 literature).

Vendors carrying it in 2026 (observed 2026-09-20):

• Liberty Peptides — 5 mg vial, $99.00 (in stock; bulk tiers down to $74.25 at 21+; claims 99.8% purity, COA dated 2026-04-01)
• Peptide Works — 2 mg / 5 mg vials, ~$30.11/unit (volume pricing to $24.09 at 5+; batch-matched COA published pre-purchase)
• Ageless Peptides (wholesale price guide, April 2026) — 10 mg vial, $58.00
• Limitless Biochem (via scientificsean.wiki compound DB) — 5 mg, $38.00, US domestic, third-party tested
• EU vendor (via scientificsean.wiki) — lyophilized powder, €128, ships worldwide from Slovakia

2. Social standing

Pulse: Quiet but present in the hardcore-nootropic layer. The June-2026 community-dataset scan classifies P21 as "preclinical only." This session found: a 2026 nootropics mega-guide (rattibha/NootBro thread) devoting a full section to it, a May-2026 Medium first-person comparison piece, and a scientific wiki compound entry tracking prices. Threads keyword searches returned only irrelevant results; Facebook group searches returned zero posts.

Consensus verdict (community): Potent-on-paper neurogenic compound with an intriguing mechanism and zero human safety data — treated with respect and caution even by enthusiasts. Not a casual nootropic; the "wait months for subtle effects" framing dominates.

Recurring praise:

• Mechanism: LIF inhibition → neural progenitor self-renewal/proliferation ("true neurogenesis"), BDNF upregulation, GSK3β inhibition, reduced tau/Aβ in Alzheimer's mouse models.
• NootBro guide: "It's so powerful it will boost neurogenesis in Alzheimer's rats beyond that of healthy rats."
• Medium reviewer (May 2026): for "long-term brain health and willing to wait months for subtle effects? P21 might help."

Recurring complaints / failure modes:

• No human data, unknown safety — the dominant caution.
• Slow/subtle: months-long timelines; nothing like the acute kick of Semax.
• Cost: ~$200/month in compounded form per the Medium piece; research vials cheaper but still premium per mg.

Viral/overhyped warnings: Vendor copy ("more stable, crosses the blood-brain barrier") is extrapolated from rodent work. The claim that P21 was "developed by reverse engineering Cerebrolysin" circulates in community lore (NootBro guide) — UNVERIFIED against primary literature in this session.

Representative quotes (attributed):

• NootBro nootropics guide (rattibha, ~Sept 2026): "P21 is on another level and should not be taken lightly... human research on P21 is nonexistent and thus its safety is unknown... one should approach this compound with extreme caution."
• Same guide: "Interestingly, P21 was actually developed by reverse engineering Cerebrolysin."
• Medium first-person piece (May 2026): "P21 was $200 [per month]... Are you thinking about long-term brain health and willing to wait months for subtle effects? P21 might help."
• scientificsean.wiki P21 entry (updated 2026-08-19): "no reviews yet; be the first."

3. Social validation

Tier: Tier 3 — research chemical only: preclinical evidence, no human trials, no reviews on the main community compound database, thin social signal (one mega-guide, one first-person article, wiki price-tracking).

Named sources and what each proves:

• scientificsean.wiki P21 entry (updated 2026-08-19): proves 2026 gray-market availability and multi-vendor price points ($38/5 mg US; €128 EU); "no reviews yet" proves absent community review footprint.
• NootBro/rattibha nootropics guide (~Sept 2026): proves P21 has mindshare among hardcore nootropic writers; frames it as high-potency/high-caution.
• Medium first-person comparison (May 2026): proves real consumer trial (compounded, ~$200/mo) with a "subtle, slow" verdict.
• Threads/Facebook: zero relevant results (honest negative).
• Preclinical literature (2014 Neurobiol Dis; 2014 Neurobiol Aging; 2020 Alz Res Ther; 2022 Biomolecules review): proves the rodent evidence base exists; proves nothing about human efficacy or safety.

4. Key specs

5. Pricing (observed 2026-09-20)

• MSRP: none (research chemical; no pharma product exists).
• Street price: US gray-market ~$30–$100 per 5 mg vial depending on vendor; compounded/clinic channel ~$200/month (Medium, May 2026).
• Facebook Marketplace: no listings observed — say so honestly.

6. What's included / what's needed

• Included: sealed vial of lyophilized powder (2/5/10 mg) — research use only, per all vendor disclaimers.
• Needed: bacteriostatic water for reconstitution, syringes, alcohol swabs (standard research-peptide handling). Vendors explicitly disclaim human/animal use and provide no dosing information.

7. Support reality

• Manufacturer support: none — no pharmaceutical manufacturer; synthesized by contract labs for research-chemical vendors.
• Vendor COA reputation: Liberty Peptides publishes dated COAs (2026-04-01, 99.8% purity, endotoxin data); Peptide Works publishes batch-matched COAs pre-purchase; Limitless Biochem is third-party tested per the wiki. These are vendor-supplied documents, not independent verification.
• Counterfeit/mislabeling risk: inherent to the research-chemical market; no pharma reference standard exists to compare against. No community adulteration reports surfaced this session (not observed).

8. Community verdict

P21 sits at the speculative edge of the category: a genuinely interesting preclinical neurogenic mechanism (CNTF-fragment, LIF inhibition) wrapped in zero human data and explicit community caution. Enthusiasts track it, almost nobody reviews it, and the honest consensus is "approach with extreme caution" — it is a research chemical, not a nootropic with a safety record.

9. Regulatory & safety status

• Regulatory: Research chemical only. Not approved by FDA, EMA, or any national medicines agency for human use. No human trials published.
• Safety: unknown in humans — no clinical safety data exists. Preclinical rodent studies show neurogenic effects; nothing establishes a human safety profile, dose, or contraindications.
• Community-reported side effects: none documented in this session's extraction (no reviews exist on the main community database).
• Never imply human-use approval where none exists: P21 has no approved human-use status anywhere.

Extraction log

• Threads: 2 P21-related searches — 0 relevant edges (one general peptide-labs post, one unrelated cognitive-health question).
• Facebook: 3 groups × keyword searches — 0 matching posts.
• Web: vendor pages + scientific wiki + NootBro guide + Medium piece as cited. No substitutions; no dosing protocol found (recorded as UNVERIFIED).
• No real product photos available. No P21 images were captured in this session (0/8 views present in img/); vendor listing images were not verifiably captured as distinct real photos. Do not treat the absence of photos as a data point about the compound.

Not medical advice. This is a research summary of vendor and community information, not a recommendation. P21 is an unapproved research chemical with no human safety data; it is not for human use.

Named sources

• scientificsean.wiki P21 entry (updated 2026-08-19) — proves 2026 gray-market availability and multi-vendor price points ($38/5 mg US (2026-08-19)
• NootBro/rattibha nootropics guide (~Sept 2026) — proves P21 has mindshare among hardcore nootropic writers (Sept 2026)
• Medium first-person comparison (May 2026) — proves real consumer trial (compounded, ~$200/mo) with a "subtle, slow" verdict. (May 2026)
• Preclinical literature (2014 Neurobiol Dis; 2014 Neurobiol Aging; 2020 Alz Res Ther; 2022 Biomolecules review) — proves the rodent evidence base exists (2014)
• NootBro guide — NootBro guide: "It's so powerful it will boost neurogenesis in Alzheimer's rats beyond that of healthy rats." - Medium reviewer (May 2026): for "long-term brain health and willing to wait months for subtle effects? (May 2026)
• Medium review — Medium reviewer (May 2026): for "long-term brain health and willing to wait months for subtle effects? (May 2026)
• Threads/Facebook — zero relevant results (honest negative).

Source URLs were not recorded for these references.